Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, Li L, Press MF, Gambhir SS, Williams LE, Wong JY, Raubitschek AA, Shively JE, Wu AM. Olafsen T, et al. Among authors: anderson al. Cancer Res. 2005 Jul 1;65(13):5907-16. doi: 10.1158/0008-5472.CAN-04-4472. Cancer Res. 2005. PMID: 15994969 Free PMC article.
Monodispersed DOTA-PEG-conjugated anti-TAG-72 diabody has low kidney uptake and high tumor-to-blood ratios resulting in improved 64Cu PET.
Li L, Turatti F, Crow D, Bading JR, Anderson AL, Poku E, Yazaki PJ, Williams LE, Tamvakis D, Sanders P, Leong D, Raubitschek A, Hudson PJ, Colcher D, Shively JE. Li L, et al. Among authors: anderson al. J Nucl Med. 2010 Jul;51(7):1139-46. doi: 10.2967/jnumed.109.074153. Epub 2010 Jun 16. J Nucl Med. 2010. PMID: 20554731 Free PMC article.
Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improved 64-copper PET imaging.
Li L, Crow D, Turatti F, Bading JR, Anderson AL, Poku E, Yazaki PJ, Carmichael J, Leong D, Wheatcroft D, Raubitschek AA, Hudson PJ, Colcher D, Shively JE. Li L, et al. Among authors: anderson al. Bioconjug Chem. 2011 Apr 20;22(4):709-16. doi: 10.1021/bc100464e. Epub 2011 Mar 24. Bioconjug Chem. 2011. PMID: 21395337 Free PMC article.
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.
Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A, Kwok C, Yamauchi D, Anderson AL, Falk P, Krishnan A, Kirschbaum M, Kogut N, Nakamura R, O'donnell M, Parker P, Popplewell L, Pullarkat V, Rodriguez R, Sahebi F, Smith E, Snyder D, Stein A, Spielberger R, Zain J, White C, Raubitschek A. Nademanee A, et al. Among authors: anderson al. Blood. 2005 Oct 15;106(8):2896-902. doi: 10.1182/blood-2005-03-1310. Epub 2005 Jul 7. Blood. 2005. PMID: 16002426 Free PMC article. Clinical Trial.
Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis.
Ammann M, Kinney MAO, Gudmundsdottir H, Santol J, Thiels CA, Warner SG, Truty MJ, Kendrick ML, Smoot RL, Anderson AL, Halfdanarson TR, Nagorney DM, Starlinger PP. Ammann M, et al. Among authors: anderson al. Ann Surg Oncol. 2024 Jun;31(6):3976-3977. doi: 10.1245/s10434-024-15264-2. Epub 2024 Apr 15. Ann Surg Oncol. 2024. PMID: 38619707 No abstract available.
Assessment of the impact of direct in vitro PFAS treatment on mouse spermatozoa.
Calvert L, Martin JH, Anderson AL, Bernstein IR, Burke ND, De Iuliis GN, Eamens AL, Dun MD, Turner BD, Roman SD, Green MP, Nixon B. Calvert L, et al. Among authors: anderson al. Reprod Fertil. 2024 Mar 8;5(1):e230087. doi: 10.1530/RAF-23-0087. Print 2024 Jan 1. Reprod Fertil. 2024. PMID: 38367345 Free PMC article.
173 results